EURETINA INNOVATION SPOTLIGHT

EURETINA Innovation Spotlight

Wednesday, 30 September 2026

VIECON - Vienna Congress & Convention Center, Vienna

Programme

Dear Colleagues,

On behalf of the Euretina Board and the EIS Organising Committee, it is my great pleasure to welcome you to the third edition of the Euretina Innovation Spotlight.

Building on the success of the past two years, the goal of Euretina remains to create a dynamic forum that fosters communication and collaboration in order to advance and improve the care of patients with retinal diseases.

EIS 2026 offers an engaging programme of presentations and panel discussions, which has been curated by members of the Euretina Executive and Board. The meeting brings together key opinion leaders in the field of ophthalmology, including physicians, researchers, industry leaders, regulators and investors.

The format of this gathering is designed to stimulate lively debate, encourage collaboration and create unique networking opportunities. It also offers the Euretina community valuable insights into the latest pipeline plans for cutting-edge retinal treatments being developed by the industry.

We are deeply encouraged by the continued interest and support from both physicians and industry representatives. We would like to thank you for your participation and look forward to a rewarding and enriching meeting.

Best wishes,



Nicole Eter
President, Euretina

EIS Organising Committee



Nicole Eter
Euretina President



Kourous Rezaei
Euretina Co-opted Board Member



Martin Zinkernagel
Euretina General Secretary



Jens Folke Kiilgaard
Euretina President Elect



Anat Loewenstein
Euretina Past President



Dara Conlon
Euretina Executive Vice President

Programme Contributors



Reza Abedian

Head of Business Development & Customer Solutions

SENSILE MEDICAL AG/GERRESHEIMER



David Almeida

Founder

CASExAI PRECISION MEDICINE LLC



Francesco Bandello

MD

VITA-SALUTE SAN RAFFAELE UNIVERSITY



Dominik Beck

Head of Business Sector Surgery Posterior Segment

ZEISS MEDICAL TECHNOLOGY



James Blaha

CEO and founder

VIVID VISION



Francesco Boscia

MD

UNIVERSITY OF BARI ALDO MORO AND POLICLINICO DI BARI



Paul Bresge

CEO

RAY THERAPEUTICS



Orestis Briasoulis

MD, Sr. VP of Medical Affairs

OCULIS



Patrick Bussfeld

Head of Medical Affairs Pipeline Eye Health

BOEHRINGER INGELHEIM



Usha Chakravarthy

MD, PhD

QUEEN'S UNIVERSITY BELFAST



Daniel Chao

Vice President and Head of Clinical Development

SURROZEN



Rodolphe Clerval

CEO

COAVE THERAPEUTICS



Laura Distefano-Dominguez

MD

RETINAROUTE MEDICAL



Brad Doerschuk

President and CEO

INFOCUS CLINICAL RESEARCH



Kenji Fujita

CMO

ATSENA THERAPEUTICS



Andrea Giani

Chief Medical Officer

MGSHELL SRL



Anta Gkelou

PhD

SOFINNOVA PARTNERS



Mahmut Gökkan

Founder

AI4VISION HEALTH TECHNOLOGIES INC



Ulrich Granzer

CEO

GRANZER REGULATORY CONSULTING & SERVICES



Abhi Gupta

Executive Vice President, Commercial & Business Development

OCUGEN INC



Erin C. Henry

PhD, AVP Ophthalmology, Global Medical & Scientific Affairs

MSD EYE BIO



Nancy M. Holekamp

MD, Principal Global Medical Science Leader PDMA Ophthalmology

ROCHE



Frank G. Holz

MD

UNIVERSITY HOSPITAL BONN



Horia Ijacu

Head of International Eyecare & Specialty

ABBVIE



Daniel Jones

PhD, Head of Global Medical Affairs, SY-FOVRE and EMPAVELI

BIOGEN



Peter K. Kaiser

MD, Chief Development Officer

OCULAR THERAPEUTIX



Arshad Khanani

MD, MA

SIERRA EYE ASSOCIATES



Semin Kim

Assistant Manager Global Business

SANGMYUNG INNOVATION



David Kirn

MD, Chief Executive Officer

4D MOLECULAR THERAPEUTICS



Caroline Klaver

MD, PhD

RADBOUD UNIVERSITY MEDICAL CENTER



Laura Kovanda

PhD, VP, Team Lead, Asset Lead, BioPharma and Ophthalmology Development

ASTELLAS PHARMA INC.



Ash Kras

CEO and Co-founder

SANRO HEALTH



Alistair Laidlaw

Co-founder

COMPLOG CLINICAL VISION MEASUREMENT SYSTEMS LTD



Paolo Lanzetta

MD

UNIVERSITY OF UDINE



Sergio Leal

MD, Vice President Ophthalmology Development Lead

BAYER



Bart Leroy

MD, PhD

GHENT UNIVERSITY HOSPITAL

Programme Contributors



Luis Lesmes

CEO

ADAPTIVE SENSORY TECHNOLOGY



Amber Lewis

Director II, Clinical Development

ABBVIE



Robert MacLaren

MB, ChB

UNIVERSITY OF OXFORD



Stéphanie Magazzeni

Chief Scientific Officer

HEIDELBERG ENGINEERING



Virginia Mares

MD, PhD

RETINSIGHT



Carl-Joe Mehanna

Co-founder

ARTBRAINS SAS



Andreas Mitsios

Founder EyeLinked

ALCMAEON VISION SINGLE MEMBER P.C.



Jordi Monés

MD, PhD

INSTITUT DE LA MÀCULA



Jane Moseley

Senior Scientific Officer

EUROPEAN MEDICINES AGENCY



Tomas Navratil

PhD, Chief Development Officer

GLAUKOS CORPORATION



Babak Nemati

PhD

STRATEGIC INTELLIGENCE, INC.



Tunde Peto

MD, PhD

QUEEN'S UNIVERSITY BELFAST



Elisa Petris

PhD

SYNCONA



Roberto Pineda

MBA

ALCON



Nikolas Pontikos

EYE2GENE



Carlos Quezada-Ruiz

MD, FASRS, Chief Medical Officer

ALKEUS



Kamilla Rolsted

CEO and Co-founder

EYGO BIO



Hendrik P.N. Scholl

CMO

BELITE BIO



Star Seyedkazemi

PharmD, Vice President of Development, Lilly Genetics Medicines Chief Development Officer, and Site Head

ADVERUM BIOTECHNOLOGIES, INC.



Matthew Simunovic

RETINAL REPAIR INTERNATIONAL PTY LTD



Sobha Sivaprasad

DM

MOORFIELDS EYE HOSPITAL NHS FOUNDATION TRUST



Alfred Stett

CEO

OKUVISION GMBH



Jan Tode

Provider

OD-OS MACUTHERM



Adnan Tufail

MBBS, MD

MOORFIELDS EYE HOSPITAL NHS FOUNDATION TRUST



Patricia Udaondo Mirete

MD, PhD

UNIVERSITY OF VALENCIA



Matt Van de Ven

CEO

MACUMIRA MEDICAL DEVICES INC.



John VeLure

CEO

I-LUMEN SCIENTIFIC, INC.



Ben Yerxa

PhD, President and Co-Founder

OPUS GENETICS



Philipp Zeitschel

CEO

SUPER CODE DOCTORS GMBH



Roger Zhang

PhD

TCGX ASIA



Sandrine Zweifel

MD

UNIVERSITY HOSPITAL ZURICH

PLATINUM SPONSORS

abbvie

MSD

EyeBio
EyeBio, a wholly-owned subsidiary of Merck & Co., Inc., Rahway, N.J., USA

GOLD SPONSORS

astellas

BAYER

Belite BIO

Boehringer Ingelheim

GLAUKOS
TRANSFORMING VISION

RAY THERAPEUTICS

Roche

SILVER SPONSORS

ADVERUM
A wholly owned subsidiary of Eli Lilly and Company

Alkeus PHARMACEUTICALS

Biogen

EYEPOINT

INFOCUS CLINICAL RESEARCH

HEIDELBERG ENGINEERING

ocugen

OCULAR THERAPEUTIX
Retina experience redefined™

Oculis

OPUS GENETICS

RETINSIGHT
AI TO EYE

ZEISS

BRONZE SPONSORS

4DMT

Adaptive Sensory Technology

Alcon

ATSENA THERAPEUTICS

neurotech

Emerging Companies

AI4VISION

AB

CASExAI

coave THERAPEUTICS

TOUKANLABS

Eye2Gene™

EyeLinked
CONNECTING EYE CARE. ANYWHERE.
Ophthalmic Triage & Access Platform

Eygo Bio

gerresheimer

i-LUMEN SCIENTIFIC

MacuMira

MacuTherm®

MgShell

okuvision

RetinaRoute MEDICAL

Retairi
RETINAL REPAIR INTERNATIONAL

Sanro Health

SM Innovation

SUPER CODE DOCTORS

Surrozen

VIVID vision

Overview of Programme Schedule

12.00	**Registration & Networking**
13.00	OPENING Nicole Eter, MD Kourous Rezaei, MD
13.06	SESSION 1 (24 Minutes) **Non-Neovascular AMD** **Moderators:** Kourous Rezaei, MD & Frank G. Holz, MD
13.32	SESSION 2 (54 Minutes) **VEGF Related Retinal Indications** **Moderators:** Anat Loewenstein, MD, MHA & Francesco Bandello, MD
14.28	SESSION 3 (38 Minutes) **Inherited and Rare Retinal Diseases** **Moderators:** Bart Leroy, MD, PhD & Caroline Klaver, MD, PhD
15.08	(23 Minutes) **Keynote Lecture by Jane Moseley** **Moderators:** Nicole Eter, MD, Kourous Rezaei, MD & Ulrich Granzer, PhD
15.33	(17 Minutes) **Investor Panel** **Moderators:** Kourous Rezaei, MD & Martin Zinkernagel, MD, PhD
15.51	Posters & Networking (28 Minutes)
16.20	SESSION 4 (39 Minutes) **VEGF Related and Other Retinal Indications** **Moderators:** Nicole Eter, MD & Paolo Lanzetta, MD
17.01	SESSION 5 (27 Minutes) **Innovations in Retinal Surgery and Imaging** **Moderators:** Patricia Udaondo, MD, PhD & Jens Folke Kiilgaard, MD, PhD
17.30	(39 Minutes) **Rapid Fire Presentations by Emerging Companies** **Moderators:** Martin Zinkernagel, MD, PhD & Arshad Khanani, MD, MA
18.10	**CLOSING REMARKS** Nicole Eter, MD & Kourous Rezaei, MD
18.14	**Posters & Networking**

Full Programme

12.00 – 13.00 | Registration & Networking

13.00 – 13.05 | Opening

Nicole Eter, MD
Kourous Rezaei, MD

13.06 – 13.30 | SESSION 1
Non-neovascular AMD
Moderators: Kourous Rezaei, MD & Frank G. Holz, MD

13.06 – 13.11 **Laura Kovanda, PhD, Astellas Pharma**
The Promise and Challenges of Regenerative Medicine: Clinical Development of Cell and Gene Therapies

13.12 – 13.15 **Daniel Jones, PhD, Biogen**
Biogen: Continuing the Apellis Commitment to Innovation in Retina

13.16 – 13.30 **Panel Discussion / Q&A**
Moderators: Kourous Rezaei, MD
Frank G. Holz, MD

Laura Kovanda, PhD, Astellas Pharma Inc.
Luis Lesmes, PhD, Adaptive Sensory Technology
Usha Chakravarthy, MD, PhD, Queen's University Belfast
Sandrine Zweifel, MD, University Hospital Zurich

13.32 – 14.26 | SESSION 2
VEGF Related Retinal Indications
Moderators: Anat Loewenstein, MD, MHA & Francesco Bandello, MD

13.32 – 13.37 **Amber Lewis, PharmD, PSM, AbbVie**
Exploring the Potential of Gene Therapy in Neovascular AMD

13.38 – 13.48 **Erin C. Henry, PhD, MSD Eye Bio**
MSD in Ophthalmology

13.49 – 13.54 **Nancy M. Holekamp, MD, Roche**
Realizing the Promise of Port Delivery Platform: Innovation to Implementation

13.55 – 14.00 **Sergio Leal, MD, Bayer**
Future Focus: Bayer's Vision in Ophthalmology

14.01 – 14.06 **Tomas Navratil, PhD, Glaukos Corporation**
Advancing a New Frontier in Retina: Glaukos' Emerging Pipeline and Strategic Vision

14.07 – 14.26 **Panel Discussion / Q&A**
Moderators: Anat Loewenstein, MD, MHA
Francesco Bandello, MD

Amber Lewis, PharmD, PSM, AbbVie
Nancy M. Holekamp, MD, Roche
Sergio Leal, MD, Bayer
Tomas Navratil, PhD, Glaukos Corporation
Erin C. Henry, PhD, MSD Eye Bio
Sobha Sivaprasad, DM, Moorfields Eye Hospital NHS Foundation Trust

14.28 – 15.06 | SESSION 3
Inherited and Rare Retinal Diseases
Moderators: Bart Leroy, MD, PhD & Caroline Klaver, MD, PhD

14.28 – 14.33 **Hendrik P.N. Scholl, MD, Belite Bio**
Belite Bio Company Overview

14.34 – 14.37 **Abhi Gupta, MBA, Ocugen**
Ocugen Company Overview

14.38 – 14.41 **Ben Yerxa, PhD, Opus Genetics**
Advancing the Future of IRDs: Opus Genetics Clinical Development Update

14.42 – 14.47 **Paul Bresge, BA, Ray Therapeutics**
Development of Bioengineered Intravitreal Optogenetic Gene Therapies for Vision Restoration in Retinal Degenerative Diseases

14.48 – 14.51 **Carlos Quezada-Ruiz, MD, Alkeus**
Harnessing Breakthrough Science to Transform Care for Patients with Retinal Diseases

14.52 – 15.02 **Panel Discussion / Q&A**
Moderators: Bart Leroy MD, PhD
Caroline Klaver, MD, PhD

Hendrik P.N. Scholl, MD, Belite Bio
Paul Bresge, BA, Ray Therapeutics
Kenji Fujita, MD, Atsena Therapeutics
Robert MacLaren, MB, ChB, University of Oxford

15.03 – 15.06 **Guest Speaker**
Instruction: Kourous Rezaei, MD

15.08 – 15.31
Keynote Lecture by Jane Moseley
Moderators: Nicole Eter, MD, Kourous Rezaei, MD & Ulrich Granzer, PhD

15.08 – 15.15 **AI - an EU Regulators Perspective**
Jane Moseley, EMA
Keynote Lecture

15.16 – 15.31 **Panel Discussion / Q&A**
Moderators: Nicole Eter, MD
Kourous Rezaei, MD
Ulrich Granzer, PhD, Granzer Regulatory Consulting & Services

15.33 – 15.50
Investor Panel
Moderators: Kourous Rezaei, MD & Martin Zinkernagel, MD, PhD

Round Table Discussion
Elisa Petris, PhD, Syncona, **Roger Zhang,** PhD, TCGX Asia, **Anta Gkelou,** PhD, Sofinnova Partners, **Babak Nemati,** PhD, Strategic Intelligence, Inc.

15.51 – 16.19 | Posters & Networking

16.20 – 16.59 | SESSION 4
VEGF Related and Other Retinal Indications
Moderators: Nicole Eter, MD & Paolo Lanzetta, MD

16.20 – 16.25 **Horia Ijacu, MD, AbbVie**
Preserving Vision through Collaboration

16.26 – 16.29 **Peter K. Kaiser, MD, Ocular Therapeutix**
Ocular Therapeutix: Redefining the Retina Experience

16.30 – 16.33 **Orestis Briasoulis, MD, Oculis**
Oculis' Late-stage Breakthrough Innovation in Neuro-Ophthalmology

16.34 – 16.39 **Patrick Bussfeld, MD, Boehringer Ingelheim**
Exploring New Frontiers in Ophthalmology

16.40 – 16.43 **Star Seyedkazemi, PharmD, Adverum Biotechnologies, Inc.**
Advancing Gene Therapy in Neovascular Age-Related Macular Degeneration: Ixo-vec Program Update

16.44 – 16.59 **Panel Discussion / Q&A**
Moderators: Nicole Eter, MD
Paolo Lanzetta, MD

Horia Ijacu, MD, AbbVie
Patrick Bussfeld, MD, Boehringer Ingelheim
David Kirn, MD, 4DMT
Adnan Tufail, MBBS, MD, Moorfields Eye Hospital NHS Foundation Trust

17.01 – 17.28 | SESSION 5
Innovations in Retinal Surgery and Imaging
Moderators: Patricia Udaondo, MD, PhD & Jens Folke Kiilgaard, MD, PhD

17.01 – 17.04 **Dominik Beck, PhD, ZEISS Medical Technology**
Advancing Retinal Care in Imaging and Surgery

17.05 – 17.08 **Stéphanie Magazzeni, MD, Heidelberg Engineering**
From the Clinic to the OR: The Digital Transformation of Retina

17.09 – 17.12 **Brad Doerschuk, BA, InFocus Clinical Research**
The Retina Trial Bottleneck: Clinical Study Saturation and Site Scarcity

17.13 – 17.16 **Virginia Mares, MD, PhD, RetInSight**
From AI-enabled Biomarker Analysis to the Next Generation of Clinical Trials

17.17 – 17.28 **Panel Discussion / Q&A**
Moderators: Patricia Udaondo, MD, PhD
Jens Folke Kiilgaard, MD, PhD

Roberto Pineda, MBA, Alcon
Francesco Boscia, MD, University of Bari Aldo Moro and Policlinico Di Bari
Daniel Ting, MD, PhD, The Johns Hopkins University

17.30 – 18.09
Rapid Fire Presentations by Emerging Companies
Moderators: Martin Zinkernagel, MD, PhD & Arshad Khanani, MD, MA

Tunde Peto, MD, PhD, Queen's University Belfast
Jordi Monés, MD, PhD, Institut De La Màcula

17.30 – 17.32 **Kamilla Rolsted, PD, Eygo Bio**
Eygo Bio: A Novel Neuroprotective Approach to Geographic Atrophy

17.33 – 17.34 **Q & A**

17.35 – 17.37	**Rodolphe Clerval, MSc, Coave Therapeutics** Unlocking Scalable Retina Gene Therapy Through a Delivery-First Strategy
17.38 – 17.39	**Q & A**
17.40 – 17.42	**Andrea Giani, MD, MgShell Srl** Improving Real-World Outcomes in Retinal Diseases Through a Novel Intravitreal Bioresorbable Sustained-Release Implant
17.43 – 17.44	**Q & A**
17.45 – 17.47	**Matthew Simunovic, MD, PhD, Retinal Repair International Pty Ltd** A Light-Activated Retinal Adhesive Platform for Retinal Detachment Repair: From Preclinical Validation to Clinical Translation
17.48 – 17.49	**Q & A**
17.50 – 17.52	**Jan Tode, MD, OD-OS MacuTherm** MacuTherm® – Transforming Dry AMD Care: Halting Progression of AMD Already at Early Stages by Photothermal Stimulation
17.53 – 17.54	**Q & A**
17.55 – 17.57	**John VeLure, i-Lumen Scientific, Inc.** The i-Lumen AMD System - A Novel, Non-Invasive Bioelectric Stimulation Improving Vision for Those With Intermediate to Advanced Dry Age-Related Macular Degeneration
17.58 – 17.59	**Q & A**
18.00 – 18.02	**David Almeida, MD, PhD, CASExAI Precision Medicine LLC** SurgVectorAI: The Digital Cockpit for Quantitative Retinal Gene Therapy Dosing
18.03 – 18.04	**Q & A**
18.05 – 18.07	**Alistair Laidlaw, MD, COMPlog Clinical Vision Measurement Systems Ltd (in collaboration with ToukanLabs Ltd)** COMPlog: Precise and Reliable Clinical Vision Measurement For The Digital Era. So Much More Than An Acuity Chart
18.08 – 18.09	**Q & A**
18.10 – 18.13	**CLOSING REMARKS** Nicole Eter, MD & Kourous Rezaei, MD
18.14	**Posters & Networking**

EURETINA
INNOVATION
SPOTLIGHT

Thank you for your participation

See you next year!

Wednesday, 15 September 2027

Bella Center

Copenhagen, Denmark

